The Molecular Biology of Cancer: A Bridge from Bench to Bedside
Format: PDF / Kindle (mobi) / ePub
The Molecular Biology of Cancer, Stella Pelengaris & Michael Khan
This capturing, comprehensive text, extensively revised and updated for its second edition, provides a detailed overview of the molecular mechanisms underpinning the development of cancer and its treatment.
“Bench to Bedside”: A key strength of this book that sets it apart from general cancer biology references is the interweaving of all aspects of cancer biology from the causes, development and diagnosis through to the treatment and care of cancer patients – essential for providing a broader view of cancer and its impact.
The highly readable presentation of a complex field, written by an international panel of researchers, specialists and practitioners, would provide an excellent text for graduate and undergraduate courses in the biology of cancer, medical students and qualified practitioners in the field preparing for higher exams, and for researchers and teachers in the field.
For the teaching of cancer biology, special features have been included to facilitate this use: bullet points at the beginning of each chapter explaining key concepts and controversial areas; each chapter builds on concepts learned in previous chapters, with a list of key outstanding questions remaining in the field, suggestions for further reading, and questions for student review. All chapters contain text boxes that provide additional and relevant information.
Key highlights are listed below:
- An overview of the cancer cell and important new concepts.
- Selected human cancers: lung, breast, colorectal, prostate, renal, skin, cervix, and hematological malignancies.
- Key cellular processes in cancer biology including (a) traditionally important areas such as cell cycle control, growth regulation, oncogenes and tumour suppressors apoptosis, as well as (b) more highly topical areas of apoptosis, telomeres, DNA damage and repair, cell adhesion, angiogenesis, immunity, epigenetics, and the proteasome.
- Clinical oncology: In-depth coverage of important concepts such as screening, risk of cancer and prevention, diagnoses, managing cancer patients from start to palliative care and end-of-life pathways.
- Chapters highlighting the direct links between cancer research and clinical applications.
- New coverage on how cancer drugs are actually used in specific cancer patients, and how therapies are developed and tested.
- Systems Biology and cutting edge research areas covered such as RNA interference (RNAi).
- Each chapter includes key points, chapter summaries, text boxes, and topical references for added comprehension and review.
- Quotations have been used in each chapter to introduce basic concepts in an entertaining way.
- Supported by a dedicated website at www.blackwellpublishing.com/pelengaris
We should list the great reviews we got for first edition which are on the back of the 2nd edition:
“A capturing, comprehensive, clearly written and absolutely accurate introduction into cancer biology…..This book deserves great praise for the readable presentation of this complex field….the true synthesis of bench and bedside approaches is marvelously achieved.” Christian Schmidt, Molecular Cell
“Chapters address the issues of cancer diagnosis, treatment, and patient care and set the book apart from general molecular biology references….This book is applicable to both graduate and undergraduate students, and in the context of a research laboratory, this book would be an excellent resource as a reference guide for scientists at all levels.” V.Emuss, Institute of Cancer Research, London.
Also, from the first edition:
“Pelengaris, Khan, and the contributing authors are to be applauded. The Molecular Biology of Cancer is a comprehensive and readable presentation of the many faces of cancer from molecular mechanisms to clinical therapies and diagnostics. This book will be welcomed by neophyte students, established scientists in other fields, and curious physicians.” -Dean Felsher, Stanford University
context that may have occurred within the cell type, that is, between the immature cell in which c-MYC was originally activated and the differentiated cell resulting from subsequent (brief) inactivation of c-MYC. In this tumor model, although c-MYC expression is initiated in immature osteoblasts during embryogenesis, subsequent inactivation of c-MYC in osteogenic sarcoma cells induces differentiation into mature osteocytes. Therefore, reactivation of c-MYC now takes place in a different cellular
congenital polycythemia. Furthermore, several disorders of abnormal ubiquitin regulatory signaling are also known including at least two subtypes of Fanconi anemia and the BRCA1 and BRCA2 forms of breast and ovarian cancer susceptibility. Many other disorders affect ubiquitin pathways secondarily. Loss of von Hippel–Lindau (VHL) protein function results in an autosomal-dominant cancer syndrome known as VHL disease, which manifests as angiomas of the retina, hemangioblastomas of the central
Hodivala-Dilke, K.M. (2011). The role of β3-integrins in tumor angiogenesis: context is everything. Current Opinions in Cell Biology, 23(5): 630–7. Samuel, M.S., Lopez, J.I., McGhee, E.J., et al. (2011). Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell, 19: 776–91. Vermeer, P.D., Einwalter, L.A., Moninger, T.O., et al. (2003). Segregation of receptor and ligand regulates activation of
useful “model organism” to unravel human physiology and disease. The genome is transcribed into mRNA, and the mRNA is then translated into proteins. The human genome codes for at least 30 000 genes (the number of functional genes is still a matter of much debate), which are transcribed into many more mRNAs that code for a suggested well over 100 000 proteins. At each level, many variations occur making the system very complex (Fig. 20.1). Individuals differ on the genome level by approximately
1670. Rosenberg, S.A., Yang, J.C., and Restifo, N.P. (2004). Cancer immunotherapy: moving beyond current vaccines. Nature Medicine, 10: 909. Spratt, J.S. Jr. (1999). Cancer mortality after nonmelanoma skin cancer. Journal of the American Medical Association, 281(4): 325. Von Hoff, D.D., Lorusso, P.M., Rudin, C.M., et al. (2009). Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. New England Journal of Medicine, 361(12): 1164. Prostate Cancer Beer, T.M., Ryan, C.W.,Venner,